OncLive TV

Michael B. Atkins, MD, discusses the importance of the Georgetown Lombardi Cancer Center Consortium.

Alessandro Gronchi, MD, discusses ​the results of the ​phase 2 TRASTS trial in soft tissue sarcoma.

Daniel H. Ahn, DO, discusses the evolution of targetable alterations in colorectal cancer.

Brandon Mahal, MD, discusses the potential role of race with regard to molecular disparities among men with prostate cancer.

Monica L. Baskin, PhD, discusses treatment considerations in prostate cancer.

Alan P. Z. Skarbnik, MD, discusses factors to consider in selecting between BTK inhibitors in mantle cell lymphoma.

Ruben A. Mesa, MD, discusses management strategies for patients with myeloproliferative neoplasms.

Farrukh Awan, MD, discusses treatment options in the first relapsed setting in patients with chronic lymphocytic leukemia.

Arun Azad, PhD, discusses the significance of the PROfound trial in metastatic castration-resistant prostate cancer.

Philip W. Kantoff, MD, discusses future research efforts in prostate cancer.

Neal D. Shore, MD, FACS, discusses unmet needs in nonmetastatic castration-resistant prostate cancer.

Daniel P. Petrylak, MD, discusses future research in prostate cancer.

Sarah Nagle, MD, discusses the evolution of daratumumab administration in multiple myeloma.

Sara M. Tolaney, MD, MPH, discusses the potential role of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer and brain metastases.

Axel Grothey, MD, discusses combination therapies with regorafenib and trifluridine/tipiracil in colorectal cancer.

Alan P. Z. Skarbnik, MD, discusses treatment considerations in chronic lymphocytic leukemia.

Gary K. Schwartz, MD, discusses the benefit of dose reducing ipilimumab plus nivolumab in metastatic sarcomas.

John A. Abraham, MD, FACS, discusses remaining questions with pexidartinib in tenosynovial giant cell tumor.

Gina Z. D'Amato, MD, discusses the limitations of liquid biopsy in sarcoma.

Robert G. Maki, MD, PhD, FACP, FASCO, discusses the utility of IDH1/2 inhibitors in chondrosarcoma.

Thorvardur Halfdanarson, MD, discusses the evolving role of immunotherapy in colorectal cancer.

Nilofer S​aba Azad, MD, discusses future research efforts in colorectal cancer.

Brian T. Hill, MD, PhD, discusses the impact of the coronavirus disease 2019 pandemic on patients with mantle cell lymphoma.

Ray McDermott, discusses preventing recurrence in patients with very high-risk prostate cancer.

Maha Hussain, MD, FACP, FASCO, discusses the importance of meaningful effect in prostate cancer trials.

Seema A. Bhat, MD, discusses the results of the phase 3 ELEVATE-TN trial in patients with treatment-naïve CLL.

Zarnie Lwin, MBBS, FRACP, discusses the design of the phase 2 LEAP-005 trial in previously treated patients with advanced solid tumors.

Alan P. Z. Skarbnik, MD, discusses frontline treatment considerations in chronic lymphocytic leukemia.

John A. Abraham, MD, FACS, discusses the clinical utility of pexidartinib in tenosynovial giant cell tumor.

Brian T. Hill, MD, PhD, discusses the FDA approval of brexucabtagene autoleucel for patients with relapsed/refractory mantle cell lymphoma.